Abstract: A method for retaining ophthalmological agents in ocular tissues is provided comprising complexing an ophthalmological drug or reagent with a sulfated glucan sulfate such as cyclodextrin sulfate and contacting the complex so formed with the ocular tissue.

Abstract: Human protein kinase C and rat protein kinase C, recombinant DNA containing DNA sequence coding for kinase C, a transformant transformed with a vector containing the above recombinant DNA, and the production method of human or rat kinase C by cultivating the transformant are disclosed.Kinase C is useful as reagent for studying cellular signal transduction mechanism, as diagnostic and inspection agent for disease, for example tumor, resulting from the trouble of cellular signal transduction mechanism, and as screening agent for a preventive agent or medicine to the disease.

Abstract: The present invention discloses, a bispecific monoclonal antibody to an ansamitocin derivative and a target antigen, particularly tumor-associated antigen, which can carry an ansamitocin derivative in a stable and inactive form at other sites than the target and release the active-form ansamitocin derivative at the target site, so that an anticancer agent having excellent durability and selectivity with little adverse action can be prepared using the bispecific monoclonal antibody and ansamitocin derivatives.

Abstract: There is provided an extremely thermostable enzyme obtainable from Thermococcus litoralis. The thermostable enzyme has a molecular weight of about 90,000-95,000 daltons, a half-life of about 60 minutes at 100.degree. C. in the absence of stabilizer, and a half-life of about 95 minutes at 100.degree. C. in the presence of stabilizer, such as octoxynol (TRITON X-100) or bovine serum albumin. The thermostable enzyme possesses a 3'-5' proofreading exonuclease activity. The thermostable enzyme may be native or recombinant and may be used for second-strand cDNA synthesis in cDNA cloning, DNA sequencing, and DNA amplification.

Abstract: The present invention relates to a compound of the formula: ##STR1## wherein R.sup.1 is 2-methyl-1-propenyl group or isobutyl group; R.sup.2 is hydrogen atom, an optionally substituted aliphatic hydrocarbon residue or an optionally substituted acyl group, or a salt thereof.The compound (I) of the invention has, among others, angiogenesis inhibiting activity, cell-proliferation inhibiting activity and immune reaction inhibiting activity, thus being useful as medicines, etc.

Abstract: The present invention relates to an intravascular embolizing agent containing an angiogenesis-inhibiting substance and an intravascular embolizing substance. The agent strengthens the antitumor effect of an angiogenesis-inhibiting substance and serves to reduce the dose and undesirable side effects. And use of the agent in concert with an anti-neoplastic agent brings about further strong and long-lasting antitumor effects.

Abstract: Methods for stabilizing fibroblast growth factor (FGF) in heat, acid and/or proteolytic environments are provided. Such methods comprise combining or otherwise complexing FGF with a salt of sucrose octasulfate (SOS) and in particular with the aluminum (sucralfate) or potassium salts thereof. The present invention also provides FGF-stable compositions comprising SOS and FGF. Such compositions can be used in the treatment of FGF-responsive diseases including the treatment of wounds and ulcerative conditions of the gastrointestinal tract. The present invention also provides various diagnostic protocols employing SOS as well as diagnostic kits with SOS as a component thereof. Finally, the present invention provides methods of purifying FGF with SOS.

Abstract: The present invention relates to a portable storage unit for food or drink items which is adapted for mounting over an air ventilator of an air-conditioner or heating unit, thus allowing items stored within to be cooled or heated, as desired. Additionally, in a preferred embodiment, the unit of the present invention is formed of an insulating material thus allowing the user to remove the device from the vehicle and transport the stored items without the need for a conventional cooler.

Abstract: The present invention is related to a compound of the formula ##STR1## wherein R.sup.1 is a 2-methyl-1-propenyl or isobutyl group which may be substituted and R.sup.2 is (1) a substituted alkanoyl group, (2) a substituted aroyl group having at least one substituent selected from the group consisting of C.sub.2-6 alkyl, amino, halogen, hydroxyl, lower alkoxy, cyano, carbamoyl and carboxyl, (3) an aromatic heterocycle-carbonyl, which may optionally be substituted, (4) a carbamoyl group, which may optionally be substituted, (5) an alkyl group, which may optionally be substituted, (6) a benzenesulfonyl group, which may optionally be substituted, (7) an alkylsulfonyl group, which may optionally be substituted, (8) a sulfamoyl group, which may optionally be substituted, (9) an alkoxycarbonyl group, which may optionally be substituted or (10) a phenoxycarbonyl group, which may optionally be substituted; or a salt thereof.The compound (I) has a strong angiogenesis inhibitory activity.

Abstract: The present invention provides a novel approach to the production of restriction enzymes. More specifically, there is provided a novel method for cloning these enzymes, which comprises preparing DNA libraries from the DNA of an organism that synthesizes the restriction enzyme of interest, creating a suitable host containing a heterospecific methyltransferase gene able to protectively modify DNA from digestion by the restriction enzyme of interest, introducing the DNA libraries into the protectively modified host, and screening recombinant organisms to identify those carrying the desired restriction enzyme gene.The application of this method to the FspI and HaeIII restriction genes of Fischerella species and Haemophilus aegyptius, respectively, is described in detail, together with the resulting clones that form the basis of a new and useful process for purifying the FspI and HaeIII restriction enzymes.

Abstract: The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement-mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.

Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.

Abstract: The present invention is related to a compound of the formula ##STR1## wherein R.sup.1 is a 2-methyl-1-propenyl or isobutyl group which may be substituted and R.sup.2 is (1) a substituted alkanoyl group, (2) a substituted aroyl group having at least one substituent selected from the group consisting of C.sub.2-6 alkyl, amino, halogen, hydroxyl, lower alkoxy, cyano, carbamoyl and carboxyl, (3) an aromatic heterocycle-carbonyl, which may optionally be substituted, (4) a carbamoyl group, which may optionally be substituted, (5) an alkyl group, which may optionally be substituted, (6) a benzenesulfonyl group, which may optionally be substituted, (7) an alkylsulfonyl group, which may optionally be substituted, (8) a sulfamoyl group, which may optionally be substituted, (9) an alkoxycarbonyl group, which may optionally be substituted or (10) a phenoxycarbonyl group, which may optionally be substituted; or a salt thereof.The compound (I) has a strong angiogenesis inhibitory activity.

Abstract: The present invention is related to a compound of the formula ##STR1## wherein R.sup.1 is a 2-methyl-1-propenyl or isobutyl group which may be substituted and R.sup.2 is (1) a substituted alkanoyl group, (2) a substituted aroyl group having at least one substituent selected from the group consisting of C.sub.2-6 alkyl, amino, halogen, hydroxyl, lower alkoxy, cyano, carbamoyl and carboxyl, (3) an aromatic heterocycle-carbonyl, which may optionally be substituted, (4) a carbamoyl group, which may optionally be substituted, (5) an alkyl group, which may optionally be substituted, (6) a benzenesulfonyl group, which may optionally be substituted, (7) an alkylsulfonyl group, which may optionally be substituted, (8) a sulfamoyl group, which may optionally be substituted, (9) an alkoxycarbonyl group, which may optionally be substituted or (10) a phenoxycarabonyl group, which may optionally be substituted; or a salt thereof.The compound (I) has a strong angiogenesis inhibitory activity.

Abstract: The present invention provides a novel restriction endonuclease obtainable from the bacterium Kluyvera ascorbata, hereinafter referred to as "KasI", which endonuclease:(1) recognizes the base sequence in a double-stranded DNA molecule as shown below,5'--GGCGCC--3'3'--CCGCGG--5'(wherein C and G represent cytosine and guanine, respectively),(2) cleaves said sequence in th4e phosphodiester bonds between G and G as indicated with the vertical arrows; and(3) cleaves double-stranded pUC, M13mp18, and lambda DNA in one position, PhiX172, and T7 DNA in two positions, and Adeno2 DNA at 20 positions, while not cleaving SV40 DNA.The present invention further provides a recombinant DNA encoding the KasI restriction endonuclease and modification methylase obtainable from K. ascorbata, and methods for the production of the recombinant DNA encoding those enzymes. Methods for producing the KasI restriction endonuclease and modification methylase in substantially pure form are also provided.

Abstract: The present invention discloses, a bispecific monoclonal antibody to an ansamitocin derivative and a target antigen, particularly tumor-associated antigen, which can carry an anasamitocin derivative in a stable and inactive form at other sites than the target and release the active-form ansamitocin derivative at the target site, so that an anticancer agent having excellent durability and selectivity with little adverse action can be prepared using the bispecific monoclonal antibody and ansamitocin derivatives.

Abstract: The present invention relates to a process for producing a biaxially oriented polyester film. The process is carried out using the following steps: (a) stretching an amorphous film substantially comprising polyethylene terephthalate 1.2 to 4.0 times in the machine direction by single-stage or multi-stage process to obtain a film having an index of birefringence of 1.times.10.sup.-3 to 2.5.times.10.sup.-2 ; (b) stretching the thus obtained film 1.1 to 3.5 times in the machine direction by single-stage or multi-stage process of 3.0.times.10.sup.-2 to 8.0.times.10.sup.-2 without cooling the film to the glass transition temperature thereof or below; (c) cooling the thus obtained film to the glass transition temperature thereof or below; (d) heating the thus obtained film to the glass transition temperature or higher and stretching the film in the machine direction by a single-stage or multi-stage process at a stretching ratio which brings the overall stretching ratio of 4.0 to 9.

Abstract: Dextran sulfate, .beta.-1,3-glucan sulfate, and the salts thereof are angiostatic and useful for treatment and prevention of various diseases caused by abnormally accelerated angiogenesis. Combination of such a compound with a steroidal or non-steroidal substance increases the angiostatic activity of each compound to induce the combined effect.

Abstract: Disclosed is a method for purifying a fibroblast growth factor (FGF) protein with use of a crosslinked polysaccharide sulfate. The FGF protein is preferable a mutein, in which at least one human basic FGF-constituent amino acid is substituted by at least one different amino acid. The crosslinked polysaccharide sulfate is preferably a crosslinked cellulose sulfate, a crosslinked agarose sulfate or a crosslinked dextran sulfate. According to the present invention, FGF can be highly purified on a commercial scale, and therefore preparations containing the FGF protein can be advantageously formulated.

Abstract: The present invention provides a novel Type II restriction endonuclease obtainable from Pseudomonas alcaligenes. The endonuclease known as PacI, recognizes the following nucleotide sequence and has a cleavage point indicated by the arrows: ##STR1## Also described is a process for obtaining PacI from P. alcaligenes.